Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC).

Blumenschein, G R; Smit, E F; Planchard, D; Kim, D-W; Cadranel, J; De Pas, T; Dunphy, F; Udud, K; Ahn, M-J; Hanna, N H; Kim, J-H; Mazieres, J; Kim, S-W; Baas, P; Rappold, E; Redhu, S; Puski, A; Wu, F S; Jänne, P A.

Ann Oncol ; 26(5): 894-901, 2015 May.

Artículo en Inglés | MEDLINE | ID: mdl-25722381

2.

Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.

Bahce, I; Yaqub, M; Smit, E F; Lammertsma, A A; van Dongen, G A M S; Hendrikse, N H.

Lung Cancer ; 107: 1-13, 2017 05.

Artículo en Inglés | MEDLINE | ID: mdl-27319335

3.

A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.

Biesma, B; Smit, E F; Postmus, P E.

Lung Cancer ; 24(2): 115-21, 1999 May.

Artículo en Inglés | MEDLINE | ID: mdl-10444062

4.

Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT.

van der Meij, B S; Langius, J A E; Spreeuwenberg, M D; Slootmaker, S M; Paul, M A; Smit, E F; van Leeuwen, P A M.

Eur J Clin Nutr ; 66(3): 399-404, 2012 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-22234041

5.

[New data presented at ASCO 2002 concerning small cell bronchial cancer]. / Nouveautés présentées à l'ASCO 2002 concernant les cancers bronchiques à petites cellules.

Smit, E-F.

Rev Pneumol Clin ; 58(5 Pt 2): 3S11-4, 2002 Nov.

Artículo en Francés | MEDLINE | ID: mdl-12538926

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC).

Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.

A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.

Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT.

[New data presented at ASCO 2002 concerning small cell bronchial cancer]. / Nouveautés présentées à l'ASCO 2002 concernant les cancers bronchiques à petites cellules.

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC).

Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.

A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.

Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT.

[New data presented at ASCO 2002 concerning small cell bronchial cancer]. / Nouveautés présentées à l'ASCO 2002 concernant les cancers bronchiques à petites cellules.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC).